Dyadic International, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DYAI research report →
Companywww.dyadic.com
Dyadic International, Inc. , a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- CEO
- Mark A. Emalfarb
- IPO
- 2008
- Employees
- 6
- HQ
- Jupiter, FL, US
Price Chart
Valuation
- Market Cap
- $26.88M
- P/E
- -3.68
- P/S
- 9.04
- P/B
- -65.85
- EV/EBITDA
- -3.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 31.26%
- Op Margin
- -238.40%
- Net Margin
- -245.12%
- ROE
- -1004.96%
- ROIC
- -152.65%
Growth & Income
- Revenue
- $1.23M · -64.74%
- Net Income
- $-7,364,628 · -26.78%
- EPS
- $-0.23 · -15.00%
- Op Income
- $-7,145,916
- FCF YoY
- -43.46%
Performance & Tape
- 52W High
- $1.35
- 52W Low
- $0.65
- 50D MA
- $0.81
- 200D MA
- $0.91
- Beta
- 1.17
- Avg Volume
- 82.23K
Get TickerSpark's AI analysis on DYAI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | TCHELET RONEN | other | 18,064 |
| Jan 2, 26 | TCHELET RONEN | other | 47,250 |
| Jan 2, 26 | Rawson Ping Wang | other | 29,158 |
| Jan 2, 26 | Rawson Ping Wang | other | 47,250 |
| Jan 2, 26 | Lucy Patrick K. | other | 21,552 |
| Jan 2, 26 | Lucy Patrick K. | other | 67,500 |
| Jan 2, 26 | Lucy Patrick K. | other | 39,894 |
| Jan 2, 26 | Lucy Patrick K. | other | 21,552 |
| Jan 2, 26 | Kaye Jack | other | 21,552 |
| Jan 2, 26 | Kaye Jack | other | 67,500 |
Our DYAI Coverage
We haven't published any research on DYAI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DYAI Report →